49,123 Shares in IDEXX Laboratories, Inc. (NASDAQ:IDXX) Bought by Lazard Freres Gestion S.A.S.

Lazard Freres Gestion S.A.S. acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 49,123 shares of the company’s stock, valued at approximately $20,309,000. Lazard Freres Gestion S.A.S. owned approximately 0.06% of IDEXX Laboratories at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of IDXX. FSA Wealth Management LLC purchased a new stake in shares of IDEXX Laboratories during the third quarter worth $25,000. Rialto Wealth Management LLC acquired a new position in IDEXX Laboratories during the fourth quarter worth $30,000. Retirement Wealth Solutions LLC acquired a new position in IDEXX Laboratories during the fourth quarter worth $31,000. Ashton Thomas Securities LLC acquired a new position in IDEXX Laboratories during the third quarter worth $37,000. Finally, Kestra Investment Management LLC acquired a new position in IDEXX Laboratories during the fourth quarter worth $38,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on IDXX shares. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Barclays lifted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Leerink Partners assumed coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective on the stock. Morgan Stanley lowered their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Finally, Piper Sandler boosted their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $533.75.

IDEXX Laboratories Stock Down 3.3 %

NASDAQ IDXX opened at $412.40 on Thursday. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The stock’s 50 day moving average is $438.09 and its two-hundred day moving average is $448.02. The company has a market capitalization of $33.54 billion, a price-to-earnings ratio of 38.65, a PEG ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $550.24.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. The trade was a 49.50 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.18% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.